Biotech News

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Verrica Pharmaceuticals (VRCA)Verrica Pharmaceuticals2026-05-05 20:05 ESTClinical readout

VRCA (VRCA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vrca.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VRCAVerrica Pharmaceuticals2026-07-21 12:05 EST

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

VRCAVerrica Pharmaceuticals2026-06-22 12:05 EST

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

VRCAVerrica Pharmaceuticals2026-05-28 12:05 EST

Verrica to Participate in the Jefferies Global Healthcare Conference

VRCAVerrica Pharmaceuticals2026-05-13 12:00 EST

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

VRCAVerrica Pharmaceuticals2026-05-12 20:01 EST

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

VRCAVerrica Pharmaceuticals2026-05-05 12:00 EST

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

VRCAVerrica Pharmaceuticals2026-04-09 20:05 EST

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

VRCAVerrica Pharmaceuticals2026-04-06 12:05 EST

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

VRCAVerrica Pharmaceuticals2026-03-11 12:00 EST

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

VRCAVerrica Pharmaceuticals2026-03-05 13:00 EST

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

View all latest news

Verrica Pharmaceuticals

Verrica Pharmaceuticals is a dermatology company focused on treatments for skin conditions and office-based dermatologic procedures. Its story is centered on commercial skin-care execution rather than broad biotech breadth.

Recent company news

VRCABruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

VRCAQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

VRCAMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

VRCAAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

VRCAGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 5.44 USD
Market cap: 99.47M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States